EA202192566A1 - МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28 - Google Patents
МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28Info
- Publication number
- EA202192566A1 EA202192566A1 EA202192566A EA202192566A EA202192566A1 EA 202192566 A1 EA202192566 A1 EA 202192566A1 EA 202192566 A EA202192566 A EA 202192566A EA 202192566 A EA202192566 A EA 202192566A EA 202192566 A1 EA202192566 A1 EA 202192566A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- egfr
- egfrxcd28
- antibody
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000012270 PD-1 inhibitor Substances 0.000 abstract 1
- 239000012668 PD-1-inhibitor Substances 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000009175 antibody therapy Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 238000013415 human tumor xenograft model Methods 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002601 intratumoral effect Effects 0.000 abstract 1
- 210000003071 memory t lymphocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940121655 pd-1 inhibitor Drugs 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962822124P | 2019-03-22 | 2019-03-22 | |
| PCT/US2020/023857 WO2020198009A1 (en) | 2019-03-22 | 2020-03-20 | EGFR x CD28 MULTISPECIFIC ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192566A1 true EA202192566A1 (ru) | 2021-12-27 |
Family
ID=70228885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192566A EA202192566A1 (ru) | 2019-03-22 | 2020-03-20 | МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11912767B2 (enExample) |
| EP (1) | EP3941941A1 (enExample) |
| JP (2) | JP7659501B2 (enExample) |
| KR (1) | KR20210142659A (enExample) |
| CN (1) | CN113661177B (enExample) |
| AU (1) | AU2020247803A1 (enExample) |
| BR (1) | BR112021018442A2 (enExample) |
| CA (1) | CA3134335A1 (enExample) |
| CL (2) | CL2021002446A1 (enExample) |
| CO (1) | CO2021014076A2 (enExample) |
| EA (1) | EA202192566A1 (enExample) |
| IL (1) | IL286536A (enExample) |
| MA (1) | MA55363A (enExample) |
| MX (1) | MX2021011500A (enExample) |
| MY (1) | MY209363A (enExample) |
| PH (1) | PH12021552300A1 (enExample) |
| SG (1) | SG11202110341WA (enExample) |
| WO (1) | WO2020198009A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202012729YA (en) * | 2018-06-21 | 2021-01-28 | Regeneron Pharma | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
| US11912767B2 (en) | 2019-03-22 | 2024-02-27 | Regeneron Pharmaceuticals, Inc. | EGFR × CD28 multispecific antibodies |
| WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| AU2021369835A1 (en) * | 2020-10-30 | 2023-06-01 | Janux Therapeutics, Inc. | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| AU2021374803A1 (en) * | 2020-11-03 | 2023-06-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies |
| JP2024503027A (ja) | 2021-01-11 | 2024-01-24 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ８標的ウイルスベクターの使用方法 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| MX2024010339A (es) | 2022-02-23 | 2024-09-30 | Xencor Inc | Anticuerpos anti-cd28 x anti-psma. |
| IL314916A (en) | 2022-03-07 | 2024-10-01 | Novimmune Sa | Bispecific CD28 antibodies for targeted T cell activation |
| EP4493592A1 (en) | 2022-03-14 | 2025-01-22 | LamKap Bio gamma AG | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN118922449A (zh) * | 2022-04-11 | 2024-11-08 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd28的抗原结合分子及其医药用途 |
| CN119013295A (zh) * | 2022-04-11 | 2024-11-22 | 江苏恒瑞医药股份有限公司 | 特异性结合egfr和cd28的抗原结合分子及其医药用途 |
| US20240027432A1 (en) | 2022-07-13 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Mild acid immunoassays for detection of analytes |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| EP4598634A1 (en) | 2022-10-03 | 2025-08-13 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies |
| WO2024084052A1 (en) | 2022-10-21 | 2024-04-25 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| KR20240167595A (ko) * | 2023-05-18 | 2024-11-27 | 서울대학교산학협력단 | 항-cd40l/항-cd28 이중 특이 항체 및 이의 용도 |
| TW202519559A (zh) | 2023-07-10 | 2025-05-16 | 美商再生元醫藥公司 | 雙特異性PD-L1xCD28抗體及其使用方法 |
| WO2025026356A1 (zh) * | 2023-07-31 | 2025-02-06 | 百奥泰生物制药股份有限公司 | 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用 |
| CN120647771A (zh) * | 2024-03-15 | 2025-09-16 | 上海鑫湾生物科技有限公司 | 一种激活免疫细胞杀伤肿瘤细胞的融合蛋白及其重组病毒和用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| DK1940881T3 (en) * | 2005-10-11 | 2017-02-20 | Amgen Res Munich Gmbh | COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| ES2547142T5 (es) | 2010-02-08 | 2021-12-09 | Regeneron Pharma | Cadena ligera común de ratón |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN104558190B (zh) | 2015-01-06 | 2018-08-10 | 中国药科大学 | 一种全人源靶向EGFR/KDR的IgG样双特异性抗体 |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| PT3353212T (pt) | 2015-09-23 | 2022-01-05 | Regeneron Pharma | Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações |
| RS63660B1 (sr) | 2016-09-23 | 2022-11-30 | Regeneron Pharma | Anti-muc16 (mucin 16) antitela |
| MA46417A (fr) | 2016-09-23 | 2019-07-31 | Regeneron Pharma | Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| MA54540A (fr) * | 2018-12-19 | 2021-10-27 | Regeneron Pharma | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
| US11912767B2 (en) | 2019-03-22 | 2024-02-27 | Regeneron Pharmaceuticals, Inc. | EGFR × CD28 multispecific antibodies |
-
2020
- 2020-03-20 US US16/825,179 patent/US11912767B2/en active Active
- 2020-03-20 MY MYPI2021005486A patent/MY209363A/en unknown
- 2020-03-20 BR BR112021018442A patent/BR112021018442A2/pt unknown
- 2020-03-20 MA MA055363A patent/MA55363A/fr unknown
- 2020-03-20 CN CN202080022975.8A patent/CN113661177B/zh active Active
- 2020-03-20 EA EA202192566A patent/EA202192566A1/ru unknown
- 2020-03-20 EP EP20718108.2A patent/EP3941941A1/en active Pending
- 2020-03-20 SG SG11202110341WA patent/SG11202110341WA/en unknown
- 2020-03-20 KR KR1020217032287A patent/KR20210142659A/ko active Pending
- 2020-03-20 WO PCT/US2020/023857 patent/WO2020198009A1/en not_active Ceased
- 2020-03-20 AU AU2020247803A patent/AU2020247803A1/en active Pending
- 2020-03-20 JP JP2021556753A patent/JP7659501B2/ja active Active
- 2020-03-20 CA CA3134335A patent/CA3134335A1/en active Pending
- 2020-03-20 PH PH1/2021/552300A patent/PH12021552300A1/en unknown
- 2020-03-20 MX MX2021011500A patent/MX2021011500A/es unknown
-
2021
- 2021-09-19 IL IL286536A patent/IL286536A/en unknown
- 2021-09-21 CL CL2021002446A patent/CL2021002446A1/es unknown
- 2021-10-21 CO CONC2021/0014076A patent/CO2021014076A2/es unknown
-
2023
- 2023-02-07 US US18/165,515 patent/US12415856B2/en active Active
- 2023-09-21 CL CL2023002805A patent/CL2023002805A1/es unknown
-
2024
- 2024-08-08 JP JP2024131936A patent/JP2024160318A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020198009A8 (en) | 2020-11-19 |
| JP2024160318A (ja) | 2024-11-13 |
| CN113661177B (zh) | 2024-04-16 |
| CN113661177A (zh) | 2021-11-16 |
| MA55363A (fr) | 2022-01-26 |
| AU2020247803A1 (en) | 2021-11-11 |
| CA3134335A1 (en) | 2020-10-01 |
| MX2021011500A (es) | 2021-10-22 |
| JP2022526764A (ja) | 2022-05-26 |
| MY209363A (en) | 2025-07-03 |
| US20200299388A1 (en) | 2020-09-24 |
| WO2020198009A1 (en) | 2020-10-01 |
| BR112021018442A2 (pt) | 2022-01-11 |
| US20230322927A1 (en) | 2023-10-12 |
| CL2021002446A1 (es) | 2022-05-06 |
| CL2023002805A1 (es) | 2024-03-15 |
| US12415856B2 (en) | 2025-09-16 |
| US11912767B2 (en) | 2024-02-27 |
| KR20210142659A (ko) | 2021-11-25 |
| SG11202110341WA (en) | 2021-10-28 |
| IL286536A (en) | 2021-10-31 |
| EP3941941A1 (en) | 2022-01-26 |
| PH12021552300A1 (en) | 2022-07-04 |
| JP7659501B2 (ja) | 2025-04-09 |
| CO2021014076A2 (es) | 2021-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202192566A1 (ru) | МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28 | |
| Huehls et al. | Bispecific T‐cell engagers for cancer immunotherapy | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| PH12019500550A1 (en) | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| EA202190181A1 (ru) | Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1 | |
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
| MX2018014950A (es) | Terapia de combinacion. | |
| WO2006099141A3 (en) | Anti-mesothelin antibodies | |
| WO2019204462A3 (en) | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs | |
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| ZA202006504B (en) | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| WO2022238963A3 (en) | Genetically engineered immune cells targeting cd70 for use in treating solid tumors | |
| WO2021062085A8 (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| JP2019011317A (ja) | 溶血性レンサ球菌の菌体を含む製剤との併用療法 | |
| CA3214753A1 (en) | Dosing of bispecific t cell engager | |
| MX2023011102A (es) | Anticuerpos anti-klrg1. | |
| WO2022033978A3 (en) | Cancer treatment methods using anti-cd73 antibodies | |
| CL2025002078A1 (es) | Anticuerpos multiespecíficos egfr x cd28 | |
| JPWO2020172475A5 (enExample) | ||
| MX2025011875A (es) | Agentes de union dirigidos a celulas tumorales que expresan trop2 | |
| MX2025010217A (es) | Anticuerpos multiespecificos anti-cd3 y metodos de uso |